Brink's Wins CMA Nod on NoteMachine Divestiture for NCR Atleos Deal

The Brink's Company (NYSE: BCO) said on 8 October 2026 that the UK Competition and Markets Authority accepted in principle its proposed remedy for the pending acquisition of NCR Atleos Corporation (NYSE: NATL). The remedy is the divestiture of NoteMachine/TestLink UK, a UK-specific undertaking in lieu of a Phase 2 referral. Brink's reaffirmed the deal remains on track to close early in the first quarter of 2027 and reiterated its $200 million annual run-rate cost overlap target, to be achieved within three years of closing.

Context — why the CMA remedy matters now

The CMA raised UK-specific competition concerns with Brink's early in its review of the NCR Atleos transaction. Under the UK regime, a Phase 2 investigation is a deeper, slower probe that can extend a deal timeline by months and, in the worst case, end in prohibition. By offering to sell NoteMachine/TestLink UK, Brink's is asking the regulator to accept a structural fix instead of escalating the case.

Brink's said it has been working constructively with the CMA and is committed to selecting a suitable buyer and concluding the divestiture in a timely manner. That commitment is the operative condition: the remedy only removes the Phase 2 threat if the sale actually completes.

The company first disclosed on 30 September 2026 that the sale process was progressing and that it remained engaged with a number of prospective buyers. The 8 October acceptance in principle is the regulator's signal that the proposed buyer-and-asset package is the right shape, not that a buyer has signed.

Management framed the remedy as anticipated. Chief Executive Mark Eubanks said the potential sale "was a remedy that was contemplated in the financial metrics that Brink's has previously disclosed." That matters because it means the divestiture should not force Brink's to restate the overlap math it has already put in front of investors.

Data — what the numbers show

The headline figure is the $200 million in annual run-rate cost synergies Brink's continues to expect within three years of closing. Eubanks tied that target directly to the remedy, saying the NoteMachine/TestLink UK sale does not impact it. For a deal whose investment case rests on cost extraction, keeping the overlap number intact is the single most important data point in the announcement.

The second number is the closing window: early in the first quarter of 2027. That is the timeline Brink's reaffirmed, unchanged from prior guidance. The remedy was designed to protect that date by avoiding a Phase 2 referral.

The third is the buyer count. Brink's said it remains engaged with a number of prospective buyers but did not disclose how many, their identities, or the expected sale price. The company also did not disclose NoteMachine/TestLink UK's revenue, headcount, or standalone valuation. Those gaps matter because the proceeds from the sale will influence how the combined company's balance sheet looks at close.

Item	Detail
Remedy	Divestiture of NoteMachine/TestLink UK
Regulatory status	Accepted in principle by the CMA
Phase 2 referral	Avoided if divestiture concludes
overlap target	$200M annual run-rate, within 3 years of close
Expected close	Early Q1 2027

Analysis — what it means for markets and tickers

The remedy converts a binary regulatory risk into an execution risk. Before the CMA's acceptance in principle, the question was whether the deal would face a Phase 2 probe that could delay or kill it. Now the question is whether Brink's can find a buyer and close the NoteMachine/TestLink UK sale fast enough to satisfy the regulator.

For BCO holders, the announcement removes a tail risk without adding a new cost to the disclosed overlap math. For NATL holders, the read-through is the same: the UK leg of the approval path is now the divestiture process, not a full investigation. Both tickers are exposed to the same closing condition.

The second-order effects sit with peers in cash logistics and ATM managed services. A completed Brink's-NCR Atleos combination would create a larger competitor in cash and valuables management, digital retail solutions, and ATM managed services across the 51 countries where Brink's operates and the more than 100 countries it serves. That scale is the strategic logic of the deal and the reason the CMA looked at UK overlap in the first place.

The counter-argument is timing. An acceptance in principle is not a clearance. If the sale process stalls, the CMA can still refer the deal to Phase 2, and the early-Q1-2027 close slips. Brink's has given no deadline for signing a buyer, which leaves the schedule dependent on a process the company does not fully control.

Positioning follows the catalyst calendar. Event-driven holders of BCO and NATL are long the closing, while merger-arbitrage desks will price the residual risk as the gap between acceptance in principle and a signed sale agreement.

Outlook — what to watch next

The first catalyst is a named buyer for NoteMachine/TestLink UK. Brink's has said only that it is engaged with a number of prospective buyers; a binding sale agreement is the step that turns the CMA's acceptance in principle into a completed undertaking. The second is the CMA's formal confirmation of the remedy once that buyer is in place.

The third is the closing itself, which Brink's still guides to early in the first quarter of 2027. Any slippage in the divestiture process is the variable most likely to move that date, because it is the one condition the CMA has tied to avoiding a Phase 2 referral.

There is no price level, spread, or moving average for BCO or NATL in the company's announcement, so the levels to watch are the ones the market sets: the merger spread between the two tickers and any re-rating of BCO as the Phase 2 risk is removed. Brink's did not disclose the terms of the NoteMachine/TestLink UK sale, so proceeds remain unknown until a buyer is named.

Frequently Asked Questions

What does the CMA acceptance in principle mean for Brink's?

It means the UK regulator has agreed that selling NoteMachine/TestLink UK is the right shape of remedy to address its competition concerns, without yet formally clearing the deal. Brink's still has to select a buyer and complete the divestiture. If it does, the CMA avoids referring the NCR Atleos acquisition to a Phase 2 investigation, which is the slower and riskier path.

Does the NoteMachine/TestLink UK sale change Brink's overlap target?

No. Chief Executive Mark Eubanks said the potential sale was contemplated in the financial metrics Brink's previously disclosed and does not impact the $200 million in annual run-rate cost synergies the company still expects within three years of closing. That target is the core of the deal's investment case, so keeping it unchanged is the key financial takeaway from the announcement.

When will the Brink's acquisition of NCR Atleos close?

Brink's said the acquisition remains on track to close early in the first quarter of 2027. That timeline depends on the divestiture process concluding in a timely manner so the CMA does not refer the deal to Phase 2. Brink's has not disclosed the sale price, the buyer, or a deadline for signing a sale agreement.

Bottom Line

Brink's has traded a Phase 2 threat for a divestiture deadline, keeping its $200 million overlap target and early-2027 close intact.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.